Each year, ∼600 000 individuals worldwide are diagnosed with head and neck squamous cell carcinoma (HNSCC) ([@bib58]; [@bib24]). Despite recent advances in surgery, radiotherapy, and multimodal treatment regiments, including chemotherapy and cetuximab ([@bib5]), there has been only modest improvement in overall survival over the past 20 years ([@bib49]). Disappointedly, overall cure is achieved in \<50% of the patients ([@bib61]; [@bib1]). Patients with HNSCC with recurrent or metastatic disease have a dismal prognosis, with median survival rates of only 6--10 months ([@bib6]; [@bib49]). Established major prognostic factors are the presence of loco-regional metastasis, vascular or lymphatic invasion, positive surgical margins, and extra capsular spread of tumour cells from involved lymph nodes into soft tissue of the neck ([@bib18]). Thus, in current clinical practice, histology-based classification and clinical parameters of HNSCC are the most common predictors of patient survival ([@bib25]; [@bib43]). However, tumour-node-metastasis (TNM) staging alone is limited in its clinical capacity to provide information on prognosis and optimal treatment choice for HNSCC.

One objective of predictive oncology is to identify biomarkers that would allow the stratification of patients for treatment while avoiding under or overtreatment and preventing unnecessary therapy-related side effects ([@bib8]). Major developments including the identification of specific cancer biomarkers, including p53 and the certain involvement of human papilloma virus in oncogenesis ([@bib21]; [@bib9]) has increased our understanding of HNSCC over the last several years. Furthermore, proteins in the epithelial growth factor receptor family as well as proteins involved in cellular proliferation, apoptosis, angiogenesis, and immune response posses prognostic value ([@bib8]). Recently published data shows that genes involved in the epithelial-mesenchymal transition (EMT) were also predictive for disease recurrence in HNSCC ([@bib10]).

The described cancer biomarker Y-box-binding protein-1 (YB-1) is the focus of the present investigation. Evolutionarily YB-1 is one of the most conserved nucleic-acid-binding proteins ([@bib34]). To date, a large number of scientific articles have left little doubt that YB-1, a multifunctional protein, regulates transcription and translation by shuttling between the cytoplasm and the nucleus influencing tumour growth ([@bib50]), chemotherapy resistance ([@bib3]; [@bib35]), and EMT ([@bib16]). A predominant nuclear localisation of YB-1 protein is associated with intrinsic expression of putative oncogenes, such as human epidermal growth factor receptor 2 (HER2), PIK3CA (gene coding for human p110*α* protein), MET (proto-oncogene coding for hepatocyte growth factor receptor), and epidermal-growth-factor receptor (EGFR) ([@bib29]; [@bib4]; [@bib59]; [@bib17]), and the coordination of DNA excisional repair ([@bib13]). Moreover, several essential signalling pathways, which are activated in HNSCC, including Stat3/NF-*κ* ([@bib38]), PI3K/Akt ([@bib59]; [@bib2]), and Mek/Erk, are known to target YB-1 ([@bib11]). In view of that, YB-1 is supposed to be an important integral part of different signal transduction pathways and due to its role in cancer it is termed an oncogenic transcription/translation factor ([@bib63]).

Nuclear YB-1 is also associated with poor prognosis in various other malignancies, including ovarian, lung, synovial cancer, and glioblastoma ([@bib63]). In breast cancer YB-1 has been linked to an aggressive cancer phenotype suggesting that YB-1 may help to re-define high-risk breast cancer ([@bib23]). In breast cancer, YB-1 acts as a biomarker for predicting the efficacy of high-dose chemotherapy ([@bib22]). Increases in YB-1 protein expression has also been described for other cancers, such as osteosarcoma, prostate cancer, pancreatic adenocarcinoma, colorectal carcinoma, and medulloblastoma, indicating the clinical impact of YB-1 for the progression of these malignant diseases ([@bib36]). Elevated cytoplasmic levels of YB-1 have been linked to an increased risk of recurrence in nasopharyngeal carcinoma within a small group of patients treated by radio- or chemoradiotherapy. However, nasopharyngeal carcinoma is distinct to HNSCC in its epidemiology, biology, clinical behaviour, and treatment options, therefore not comparable to our HNSCC collective that includes classical squamous cell carcinoma head and neck tumours. It has been suggested that despite the differences in tumour biology the overexpression of YB-1 in nasopharyngeal cancer may also have clinicopathological significance as a predictive biomarker in HNSCC patients ([@bib60]). Though, it remains still unclear if YB-1 expression together with TMN staging can be used to predict survival in HNSCC at the initial time of tumour diagnosis.

Patients and methods
====================

Patients and tissue specimens
-----------------------------

Formalin-fixed, paraffin-embedded tumour resection tissue samples, including cervical lymph nodes as well as metastases, obtained from 530 patients were initially taken into account. Information related to disease-specific survival (DSS) was available from 365 patients, which were included into the study. Primary tumours sites included oral cavity, oropharynx, and hypopharynx.

All patients were treated between 1991 and 2006 by surgical resection of the primary tumour with minimum resection margins of 5 mm in all directions. All patients received a concomitant unilateral or bilateral selective neck dissection (levels I--III) initially based on tumour location. Fibro-adipose-lymphoid tissue from levels II and III were submitted for histopathological analysis intraoperatively. Where nodal metastasis (N1 or N2a cancer stage) in level II or III were identified, cervical dissection was converted to a modified radical neck dissection (levels I--V) of the affected side ([@bib48]).

No patients received adjuvant chemotherapy and also no neoadjuvant chemo- or radiochemotherapy. Thus, all patients underwent the same treatment protocol. All pT4 tumours and/or a nodal stage pN1, pN2a,b or pN3 (*n*=227, 59.5%) received adjuvant radiation therapy following the same protocol to a total dose of 65--70 Gy. All patients who refused adjuvant radiation therapy were excluded from the study. Also patients with positive resection margins, contralateral nodal metastasis, contra- or ipsilateral positive nodes larger than ⩾3 cm or those with extra-capsular spread (N2c and higher nodal stage), or those with distant metastasis at the time of surgery or predicted survival \< 1 month were not included. Tumour size (pT) and lymph node (pN) categories of the tumours were determined according to the current TNM and UICC (International Union against Cancer) classification. Follow-up was standardised for the whole collective (monthly recall in first postoperative year, six times a year in the second year, four times in the third year up to the end of the fifth year, after that once a year) and was monitored with a minimum follow-up time of 3 years, depending on the patients total lifetime.

Written consent for molecular analysis of their tissue for research purposes was obtained from all patients before surgery. Mucosa of healthy controls and tumour-free mucosa of included cancer patients served as reference control tissue for immunostaining of nuclear and cytoplasmic YB-1 expression. The study was approved by the hospitals\' ethics committee at the Klinikum rechts der Isar, Munich, Germany.

Preparation of tissue microarrays and immunohistochemical staining
------------------------------------------------------------------

For each of the 365 carcinoma patients, paraffin blocks were selected from the archives of the Institute of Pathology at the Technical University of Munich, Germany. After review of all haematoxylin and eosin stained slides, representative samples (1 mm Ø) of tumour tissues were chosen for tissue mirco arrays (TMAs). From each tumour, samples from the centre of the tumour (TC) (invasive tumour cells without any signs of normal peripheral tissue) as well as samples from the invasion front (IF) (invasive cells infiltrating the histologically normal adjacent mucosa) were selected. For construction of the TMA, core needle biopsy specimens were retrieved from the tumour blocks using a manual arrayer (Beecher Instruments, Sun Prairie, WI, USA) and positioned into a recipient paraffin array block. For the purpose of comparison, adjacent unaffected normal mucosal tissues were chosen for TMA in the same fashion. Consecutive 2 *μ*m sections were then cut from the core samples for immunohistochemical staining of YB-1 expression. Immunohistochemical staining was done by using a fluorescein isothiocyanate (FITC)-labelled rabbit antibody directed against a peptide within the C-terminus of YB-1 protein (CDGKETKAADPPAENS amide according to a previous publication ([@bib22]). After deparaffinisation, rehydration, and washing with Tris-buffered saline (TBS; 0.05 mol l^−1^ Trizma-base, 0.15 mol l^−1^ NaCl; pH 7.6), TMA sections were subjected to epitope retrieval. This was done by pressure cooking (4 min, 10 mmol l^−1^ of citrate buffer, pH 6.0), followed by endogenous peroxidase activity blocking, (with 3% H~2~O~2~ for 20 min, room temperature (RT)) in distilled water. After washing in TBS, sections were incubated with the YB-1-directed antibody (2.6 *μ*g ml^−1^, 1 h, RT) in antibody diluent (DakoCytomation, Hamburg, Germany), then followed by another TBS wash, and incubation with 100 μl of undiluted peroxidase-conjugated sheep F(ab)-anti-FITC (TUNEL-POD; Roche, Mannheim, Germany; 30 min, RT). Staining was visualised by chromogenic substrate 3.3′-diaminobenzidine addition (DakoCytomation; 10 min, RT). Finally, nuclei were then counterstained with Mayer\'s acid haematoxylin and slides were then covered using Pertex mounting medium (MEDITE, Burgdorf, Germany). As a negative control, this procedure was run omitting the primary antibody. YB-1 immunoreactivity in tumour cells was scored independently by two of the authors (NJ and MK) blinded to the clinical staging of the patients tumours. Photographs of the stained sections were taken with Zeiss Axiophot Microscope (Carl Zeiss AG, Jena, Germany) and edited with Axio Vision Release 4.8 software (Carl Zeiss AG).

Western blot analysis
---------------------

Snap-frozen tissue was homogenised according to standard protocol. Protein concentrations were determined using the BCA Protein Assay kit (Pierce, Rockford, IL, USA). Protein (30 *μ*g) was separated on 10% SDS-polyacrylamide gels and electroblotted onto Hybond-ECL nitrocellulose membrane (GE Healthcare, Munich, Germany). The membrane was incubated overnight at 4 °C in TBST (50 mmol l^−1^ Tris-HCl (pH 7.6), 150 mmol l^−1^ NaCl, 0.2% Tween 20) containing 5% fat-free dry milk (AppliChem, Darmstadt, Germany), and then probed with the YB-1 specific antibody ([@bib26]) and a YB-1 specific antibody recognising phosphorylated YB-1 (Cell Signaling, Danvers, MA, USA). To demonstrate equal loading an antibody to *α*-tubulin (Calbiochem, San Diego, CA, USA) was used. The bands were visualised using an ECL-based immunochemistry system (Roche, Penzberg, Germany). FaDu (American Type Culture Collection: HTB 43) was kindly provided by Dr O Gires (LMU Munich, Germany). CAL 33 (ACC 447) was kindly provided by Dr R Grenman (Turku University Hospital, Turku, Finland). CAL 33 and FaDu are derived from moderately differentiated squamous cell carcinomas from the tongue and hypopharynx, respectively.

Scoring of YB-1-related immunoreactivity
----------------------------------------

Semi-quantitative scoring for YB-1 immunoreactivity was carried out as described previously ([@bib29]). This scoring method assesses the percentage of malignant cells that show cytoplasmic and nucleic staining within a tissue core. YB-1 staining of normal cells in adjacent benign mucosa tissue areas was defined as background and subtracted from the scores within the tumour tissue, resulting in value that reflects 'overexpression\' within tumour areas for further analysis. Scoring results of the tumour areas were classified as follows: score 0 -- no tumour cells with immunoreactivity; score +1 -- weak reactivity, \<20% of tumour cells positive; score 2+ -- moderate activity, 20--50% of tumour cells positive; score 3+ -- strong activity with 50--80% of tumour cells positive; score 4+ -- strong to complete activity, 80--100% of tumour cells positive.

Statistical analyses
--------------------

Protein expression values for YB-1 were correlated with pT, pN status, histological grading (G) and DSS. Descriptive statistics for quantitative variables are given as the mean±s.d. and where appropriate, as medians and ranges.

Tumour site, pT, and nodal status as well as the addition adjuvant radiation therapy were randomised within the subgroups to exclude radiotherapy as a confounder.

Death was categorised as death due to HNSCC. For this analysis, the 5-year DSS in months was used as a dependent variable. For DSS analysis, patients were followed clinically from the time of initial diagnosis until their last tumour-free clinical follow-up appointment. DSS was compared with high and low nuclear *vs* cytoplasmic YB-1 expression at the IF and TC using Kaplan--Meier estimates and the log-rank test for equality of survival curves. The correlation coefficient of TNM classification, tumour grade, and YB-1 expression was calculated using the Spearman\'s rank test. Independent prognostic relevance of high YB-1 immunoreactivity and the association with probabilities of disease recurrence and DSS were adjusted using Cox proportional hazards regression models together with age, gender, histopathological tumour grade, and TNM/UICC classification. A bivariate analysis of YB-1 expression was performed where 'high\' (score 3 or 4) *vs* 'low\' (scores 0 to 2) were used. All *P*-values given are unadjusted, two-sided, and subject to a significance level of 5%. All data were analysed and figures (including plots of the Kaplan-Meier survival curves) were generated by 'Statistical Package for the Social Sciences\' (SPSS for Windows, release 18.0.0, 2009, SPSS Inc., Chicago, IL, USA).

Results
=======

Clinical characteristics of the HNSCC patients
----------------------------------------------

DSS data was available for 365 HSNCC patients. The majority of the patients were \>50 years of age at time of primary surgery (*n*=352, 96.4%) with a male predominance (*n*=291, 79.7%).

Of the latter 281 (77%) patients were tumour stage pT1/2. Of those with pT1/2 tumours 148 (40.5%) were node negative. With respect to histologic grading, ∼half of the patients (*n*=202, 55.3%) were classified as having tumours with intermediate histological grade 2 (G2), 136 (37.3%) were high-grade (G3) and 27 (7.4%) had low-grade (G1) tumours ([Table 1](#tbl1){ref-type="table"}). None of the patient\'s tumours were classified as a grade four. Median survival time for G1 was 125 month±28, for G2 73 month±9, and for G3 tumours 62 months±16. Furthermore, the 5-year DSS rate decreased significantly with increasing tumour grade; from 83% in G1 tumours, to 55% in G2 tumours, to 51% in G3 tumours (*P*\<0.01). Of the total 365 patients 62 patients (17%) recurred locally within the 5-year follow-up period. In all, 45 (72.6%) of those 62 patients developed their recurrence within the first 24 months after surgery (*P*\<0.001). The median number of months to recurrence for all of 365 patients was 31.4 within the follow-up period. Death occurred due to local or cervical tumour recurrence, distant metastasis, or secondary oral cavity carcinoma in 192 of 365 patients. Distant metastases were identified in 64 of 365 derived from the primary or a recurrent HNSCC during the total study time of 156 months.

Protein expression analysis of YB-1 in HNSCC tumour tissue specimens
--------------------------------------------------------------------

Results of the investigation of YB-1 expression in the 365 patients with HNSCC from the centre of the tumour, the IF, unaffected oral mucosa, and the oral mucosa of 10 healthy individuals were as follows. Strong staining for YB-1 protein was observed in cancer cells of the oral cavity of most of the HNSCC patients. In the cases representing the TC YB-1 staining was located in the nucleus of tumour tissue cells 88% of the time and cytoplasmic staining was observed in 63% of the cases. When looking at the tumour samples from the IF YB-1 protein expression was located in the nucleus 90% of the time and less in the respective cytoplasm (67%). Nuclear and cytoplasmic YB-1 protein expression in tumour cells of the HNSCC tissue samples was a feature of over 60% of the HNSCC cases (in the TC and IF). In contrast, faint or no YB-1 expression was observed in normal intraoral mucosa of healthy controls as well as in unaffected tumour-free mucosa of the investigated patients. [(Figure 1) (A-F)](#fig1){ref-type="fig"} indicates representative immuno-histochemical staining of variant YB-1 expression intensities in HNSCC.

In parallel, for several YB-1-positive cases selected at random, the protein was extracted from fresh-frozen tumour tissue samples and subjected to western blot analysis ([Figure 1G](#fig1){ref-type="fig"}). All three patients had tumour tissue extracts showing a YB-1 staining pattern similar to that of the oral cancer reference cell lines FaDu and CAL-33. Phosphorylated YB-1 could also be detected in all cases, indicating the presence of nuclear YB-1 in the tumour tissue of these selected patients. With respect to tumour grade and YB-1 expression, a linear relationship was not observed. [Figure 2](#fig2){ref-type="fig"} depicts the lack of statistical difference between G1, G2, and G3 tumours for YB-1 nuclear protein expression, whether expressed in the TC ([Figure 2A](#fig2){ref-type="fig"}) or in the IF ([Figure 2B](#fig2){ref-type="fig"}). However, a statistically significant increase in cytoplasmic YB-1 protein expression is demonstrated in increasing order from G1 to G3 ([Figures 2C and 3D](#fig2){ref-type="fig"}).

Protein expression of YB-1 in relation to DSS
---------------------------------------------

Based on the expression pattern of YB-1 we found that elevated nuclear YB-1 expression was associated with decreased survival of the HNSCC patients, with statistical difference (*P*=0.008 for TC samples; *P*\<0.001 for tumour IF samples) ([Figures 3A and B](#fig3){ref-type="fig"}). A low DSS rate of 41% was observed with the presence of high nuclear YB-1 expression at the IF in comparison to 67% DSS with low YB-1 expression ([Figure 3A](#fig3){ref-type="fig"}). To further verify the impact of YB-1 expression on survival, the cytoplasmic localisation of YB-1 was investigated as well. Corresponding to the data derived from nuclear expression, increased cytoplasmic YB-1 levels were also found to have a significant impact on the 5-year DSS rate (*P*=0.005 for TC; *P*=0.001 for IF) ([Figures 3C and 3D](#fig3){ref-type="fig"}).

Correlation of YB-1 expression to DSS based on histologic grading
-----------------------------------------------------------------

YB-1 expression and localisation within the different grading categories was analysed. Elevated nuclear expression of YB-1 independent of its location within the tumour was associated with significantly poorer survival of the HNSCC patients. In patients with G1 tumours the 5-year DSS rate was 89 and 85% when nuclear YB-1 expression was low at the IF and the TC, respectively, *vs* a 71% 5-year DSS for G1 grade tumours when YB-1 expression was high. For grade 2 tumours the differences were statistically significant, independent of tumour location, or the site of YB-1 expression. For G2 grade tumours the 5-year DSS for low YB-1 expression was 67% and 60% for centre and IF, respectively, compared with 39 and 44% in the high expression group. In the G3 group 5-year DSS for low YB-1 expression were 61 and 56% for TC *vs* IF compared with 43% (46%), respectively, in the high YB-1 expression group ([Table 2](#tbl2){ref-type="table"}). Results obtained for cytoplasmic YB-1 expression for TC also showed a tendency to shorter DSS but with less clarity. These results indicate that YB-1 expression at the IF is a more sensitive parameter for DSS than YB-1 expression in the TC.

Subgroup analysis of G2 tumours with respect to long-term and short-term DSS
----------------------------------------------------------------------------

Our initial data show that both nuclear and cytoplasmic YB-1 expression determined correlated with a lower 5-year DSS in HNSCC, with greatest significance at the IF ([Figure 3A and C](#fig3){ref-type="fig"}). How the combined nuclear and cytoplasmic staining (co-expression pattern) would correlate with DSS was thus investigated as a subgroup analysis. Due to statistical requirements only the important subgroup G2, which represents the vast majority of the whole collective (and is the most commonly diagnosed histologic category) was therefore further analysed. A statistically significant difference (*P*=0.001) was observed when DSS was plotted against high combined nuclear and cytoplasmic YB-1 expression at the IF *vs* low combined YB-1 protein expression of tumour cells at the IF ([Figure 4A](#fig4){ref-type="fig"}). Our results indicate that, grade 2 HNSCC patients ([Figure 4B](#fig4){ref-type="fig"}) with low YB-1 protein expression levels have a 5-year DSS rate (74%, *n*=29) similar to the G1 patient subgroup (83%, *n*=23) without YB-1 stratification. The 5-year DSS rate associated with high expression YB-1 G2 patients (38%, *n*=26) is lower than that of the survival G3 subgroup (51%, *n*=134). In further analysis of the low and high YB-1 expression groups within the G2 differentiation 21 patients out of 29 survived 5 years with combined low YB-1 expression. In contrast, only 10 patients out of 26 with high combined YB-1 expression in both compartments, nuclear as well as cytoplasmic, survived. This demonstrates that 51% more patients survived within 5 years when YB-1-combined expression was low ([Figure 4A](#fig4){ref-type="fig"}). The survival outcome difference is maintained at 7 years. DSS was as recorded at 70% in the low YB-1 combined expression group and 24% in the high YB-1 combined expression group (data not shown).

YB-1 protein expression as a statistically independent cancer biomarker in prediction of DSS of HSNCC patients
--------------------------------------------------------------------------------------------------------------

To evaluate the influence of nuclear YB-1 expression at the IF on DSS and established clinical and histomorphological parameters a multivariate Cox regression analysis was performed ([Table 3](#tbl3){ref-type="table"}). In addition to lymph node status (hazard ratio (HR)=1.45), elevated nuclear YB-1 expression at the IF was the most significant variable predicting DSS (HR=2.172). Age, histopathologic grade, and pT were not found to be statistically significant predictors of survival. A log-rank-test was also used as a second statistical model. This evaluation showed that tumour size pT (*P*=0.022) and nodal stage pN (*P*=0.001) also had a significant correlation with the DSS. Furthermore, for patients with high combined nuclear and cytoplasmic YB-1 expression at the IF (co-expression pattern group), the risk of lower DSS even further increases (HR=2.747) ([Table 3](#tbl3){ref-type="table"}).

We also analysed the correlation between YB-1 protein expression in tumour cells located at the tumour IF and those demonstrating co-expression in different subgroups defined by histological grade, pT, and nodal status at 5-year follow-up. The *χ*^2^-test showed that pT and pN, significantly correlate positively with cytoplasmic and nuclear YB-1 expression at the TC and at the tumour IF, respectively, within the entire cohort (*P*\<0.001). The log-rank test demonstrated that for T1 and T2 patients the 5-year DSS rate is influenced significantly by YB-1 protein expression in the nucleus or co-expression pattern of the nucleus plus cytoplasm. Increased levels of YB-1 protein are associated with significantly lower DSS, for pT1 (*P*=0.014) and pT2 (*P*=0.001) tumours ([Table 4](#tbl4){ref-type="table"}). For all node-negative HNSCC patients low YB-1 protein expression is associated with higher 5-year DSS rate, which is statistically significant for nuclear YB-1 protein expression at the IF (N0, *P*=0.001) and supported for the nuclear plus cytoplasmic co-expression of YB-1 demonstrating a trend without statistical significance ([Table 4](#tbl4){ref-type="table"}).

Discussion
==========

The current knowledge about the molecular mechanisms underlying disease progression and drug resistance in HNSCC is still limited. In addition, conflicting published results and disappointing clinical studies have made single cancer biomarkers highly controversial ([@bib52]). A comparative analysis of different markers and clinico-pathological features concerning their prognostic significance in oesophageal adenocarcinoma revealed that only tumour stage and lymph node involvement correlate with the survival of the patient ([@bib37]). The grade of cellular differentiation is a rather time-independent statement about the aggressiveness of the tumour (in contrast to DSS). However, it is beyond question that the grade of cellular differentiation of HNSCC to some extent influences survival. Cancer biomarkers that more accurately predict clinical outcome and response to anticancer therapy, in alignment with the established TNM and UICC classification, would still be of great advantage in the management of HNSCC patients ([@bib28]; [@bib40]).

Similar to the heat-shock proteins, the cold-shock domain protein YB-1 is thought to have a fundamental role in a wide variety of environmental stress reactions ([@bib34]). Increased expression of YB-1 in many solid tumours, such as breast cancer or melanoma, was found to be associated with malignant growth, drug resistance and poor clinical outcome ([@bib3]; [@bib50]). However, the protein expression of YB-1 in reference to the grading and DSS in HNSCC has not been examined in detail. In the present report we present clinically relevant data regarding the clinical impact of YB-1 protein expression in patients by analysing a large representative collective of untreated human tissues obtained from HNSCC patients at primary surgery, which were subjected to YB-1 specific immunohistochemistry. The statistical power associated with such a large sample size of 365 HNSCC patients combined with a follow-up period exceeding 60 months for most of the patients was a major strength of this study.

Protein expression of YB-1 determined by immunohistochemistry in the HNSCC TMAs was significantly increased in the cytoplasm as well as in the nucleus at the IF and in the centre of the tumour of the entire cohort in comparison to normal head and neck mucosal tissue ([Figure 1](#fig1){ref-type="fig"}). Interestingly, cytoplasmic but not nuclear YB-1 protein expression correlated with tumour grade in HNSCC specimens, with the highest level of expression in G3 tumours ([Figure 2](#fig2){ref-type="fig"}). Comparable studies on the same subject have not been reported so far. The only previous study concerning YB-1 protein expression in a sub-group of HNSCC was conducted in nasopharyngeal carcinoma, which dealt exclusively with cytoplasmic YB-1 protein expression ([@bib60]). Other studies conducted in the breast, ovarian cancer, and non-small cell lung cancer tissue specimens as well as osteosarcoma have in a manner similar to our data confirmed the presence of concomitant nuclear YB-1 expression together with cytoplasmic localisation of YB-1 ([@bib3]; [@bib45], [@bib44]; [@bib32]; [@bib54]).

In the next step we analysed the involvement of YB-1 expression on the 5-year DSS rates. Univariate data analyses of patients with high YB-1 expression, regardless of their within-cell localisation, were afflicted with significantly decreased 5-year DSS rates. This statistically significant result implicating a strong correlation between YB-1 expression and prognosis of the HNSCC patients may have valuable future clinical importance ([Figure 3](#fig3){ref-type="fig"}). From the multivariate analysis, which included established clinical and histomorphological factors and YB-1 staining status, translocation of YB-1 protein into the nucleus of tumour cells at the IF emerged as a statistically independent prognostic biomarker, in addition to lymph node involvement. In this context, age, histological grading, and pT were of no statistical relevance ([Table 3A](#tbl3){ref-type="table"}). Taken together, our data show clearly that nuclear YB-1 affects the DSS rates in HNSCC and is an independent prognostic biomarker. However, the results also open the interesting question why cytoplasmic YB-1 but not nuclear YB-1 correlates with grade of HNSCC.

The observed impact of nuclear YB-1 on the clinical outcome is in line with data found in prostate cancer, non-small-cell lung carcinoma and B-cell lymphoma showing that YB-1 also is a cancer biomarker for tumour aggressiveness ([@bib54]; [@bib20]; [@bib23]; [@bib65]). Additionally, YB-1 expression in breast cancer has been studied intensively, where strong clinical evidence suggests that YB-1 protein expression and its translocation from the cytoplasm to the nucleus is linked with tumour progression and could be used as an independent biomarker for aggressive breast cancer across all subtypes ([@bib23]).

Based on these results, we explored whether YB-1 protein expression could be used as a cancer biomarker for a more accurate sub-classification of high-risk HNSCC cancer patients. For this, different grading groups were separately analysed with regard to DSS and YB-1 protein expression. As shown in [Table 2](#tbl2){ref-type="table"}, in particular, the vast majority of the cohort of patients with G2 tumours with high YB-1 expression at the tumour IF, exhibited a statistically significant, shorter, DSS compared with patients with low YB-1 protein expression. This suggests that YB-1 protein expression in tumour cells located at the IF of the tumour in combination with histological grading improves prediction of clinical outcome. This might influence selection of patients who will benefit from adjuvant chemo/radiotherapy in a cohort of patients for whom it may not traditionally have been indicated. Our results are in line with data obtained by ([@bib7]), showing that the invasive front grading system is of high prognostic value for HNSCC. It should be noted, that nuclear and cytoplasmic YB-1 expression in the high and low grading groups G3 *vs* G1 has not shown statistically significant correlation with DSS. This may be due to low number of patients in G1 histologic subgroup and inhomogeneous nature of the G3 subgroup. However, despite a lack of statistical significance a tendency was observed.

In contrast to other YB-1 biomarker studies ([@bib62]), which consider nuclear YB-1 only, we also looked at the cytoplasmic expression in the evaluation of the DSS of grade 2 HNSCC patients. The application of the co-expression pattern of YB-1 at the IF in the survival analyses further amplified the discrimination of patients with grade 2 HNSCC tumours between 'short\'- and 'long\'-term survivors ([Figure 4B](#fig4){ref-type="fig"}). More specifically, the 5-year DSS record from both patient groups revealed that nearly 50% of the patients being considered as medium risk based on their histologic tumour grade were more likely to die of the disease than expected if they demonstrated high YB-1 combined expression. The data suggest that YB-1 protein expression assessed by immunohistochemistry leads to an ameliorated identification of high-risk patients. This may lead to more individualised therapy of HNSCC cancer and should be included in the post surgical analysis of grade 2 HNSCC patients to allow individualised treatment decisions with respect to adjuvant therapy in this important patient subgroup. We would suggest that before entering clinical practice, however, validation of the data in another set of HNSCC patients is essential.

It is established that YB-1 expression and localisation could affect many critical aspects of tumour biology as it is involved in fundamental processes such as mRNA splicing ([@bib56]), cell cycle ([@bib31]), drug resistance ([@bib3]), DNA repair ([@bib19]) and translational regulation ([@bib15]). Upon nuclear translocation, which is believed to be mediated by Akt and Erk through phosphorylation ([@bib11]; [@bib59]), YB-1 regulates the transcription activity by binding to gene promoter regions containing the Y-box motif, and among others, YB-1 thus may activate gene expression of the EGFR ([@bib57]), matrix metalloproteinase 2 ([@bib42]), and MET ([@bib17]), which are associated with tumour cell adhesion, invasion and metastasis in HNSCC.

The most important two recent observations include the following: (i) cytoplasmic YB-1 involvement in EMT ([@bib16]), which has a key role in cancer invasion and metastasis and (ii) YB-1 induction of CD44 expression ([@bib62]), which is a widely recognised marker for initiation of cancer cell development including initiation of the HNSCC cancer process ([@bib47]). It has been suggested that inhibition of YB-1 expression could thus minimise cancer recurrence ([@bib62]).

YB-1 expression is regulated by Twist ([@bib55]) and interferes with the mTor/Stat3 pathway ([@bib38]). Both pathways possess prognostic relevance ([@bib51]; [@bib64]; [@bib41]) and are known to have an important role in EMT, the maintenance of cancer initiating cells, and multidrug resistance ([@bib66]; [@bib39]; [@bib53]). In addition, results obtained by [@bib10]) show that the molecular determinants of EMT and NF-*κ*B are characteristics of high-risk HNSCC tumours . NF-*κ*B is also involved in regulating Twist expression ([@bib46]) and enhancing Stat3 activity in HNSCC ([@bib41]). Thus, besides YB-1, proteins such as Stat3 and Twist, hypoxia-inducible factor-*α*, and Slug have also been identified as markers of malignant progression ([@bib21]; [@bib30]; [@bib27]) and may be candidates for cancer biomarkers to be looked at in a future HNSCC biomarker screening programme.

In the clinical setting, in addition to prediction of therapy response, adequate risk-group assessment is a prerequisite for an individualised therapy concept for HNSCC ([@bib12]). This report shows that determination of YB-1 protein expression and its intracellular localisation in tumour cells at the IF are valuable molecular tools to classify grade 2 HNSCC patients into long- and short-term survivors. This may allow offering of more optimal therapeutic options for this subgroup of HNSCC patients ([@bib22]). As chemo-radiotherapy is associated with severe toxicities this decision-making process is an important one ([@bib12]).

In summary, based on our results from a large, homogenous and representative human HNSCC tissue collection, we propose that YB-1 immunohistochemistry analysis should be considered as an integral of the histomorphological diagnostic system. When this is done in conjunction with the classical histological grading system it could allow personalised treatment of high-risk groups of HNSCC patients.

Taken into account that YB-1 expression is linked to multi drug resistance in various tumour entities so far as well as against EGFR-tailored drugs ([@bib33]) YB-1 expression was also found to be also involved in cancer stem cell biology ([@bib62]) and trastuzumab resistance ([@bib14]). In light of these findings and our recent observations that YB-1-based virotherapy kills cancer stem cells equipped with nuclear YB-1 expression (Mantwill *et al*, 2011; manuscript submitted to Stem Cells), we suggest that YB-1 analysis in conjunction with YB-1 based virotherapy represents an attractive therapeutic strategy for a multimodal treatment concept for high-risk subgroup of HNSCC patients.
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![Immunoreactivity of YB-1 protein in healthy control tissue (**A**) and poorly differentiated HNSCC in TC and IF (**B**, **C** and **D**: scale bar 0.05 mm; **E** and **F**: scale bar 0.06 mm). Absent to minimal expression of cells (no score) (**A**). IF: strong nuclear expression of the tumour cells (score 3+) (**B**). Example of a well-differentiated HNSCC, with a faint to moderate staining in the tumour cells nearby the unaffected connective tissue (score 1+) (**C**). TC: strong nuclear and cytoplasmic expression of tumour cells (score 3+) (**D**). IF: weak nuclear and cytoplasmic expression of tumour cells (score 1+) (**E**). IF: moderate nuclear and cytoplasmic expression of tumour cells (score 2+) (**F**). Western blot showing YB-1 protein and phosphorylated YB-1 expression in different tumour tissues (P1-P3) and human HNSCC cell lines FaDu and CAL-33. α-tubulin served as a loading control (**G**).](bjc2011491f1){#fig1}

![Nuclear (**A** and **B**) and cytoplasmic (**C and D**) YB-1 protein expression in HNSCC tumour tissue cells in the TC (**A** and **C**) and at the IF (**B** and **D**) in relation to histological grading G1 to G3 (^\*^*P*\<0.05: G2 to G1; ^\#^*P*\<0.01: G3 to G2).](bjc2011491f2){#fig2}

![Kaplan--Meier plots illustrating the impact of YB-1 expression on DSS in the HNSSC cohort recalled for more than 60 months after surgery. Low YB-1 expression: upper blue line. High YB-1 expression: lower red line. Median DSS in patients with high/low nuclear YB-1 expression at the IF (**A**). Median DSS in patients with high/low nuclear YB-1 expression in TC (**B**). Median DSS in patients with high/low cytoplasmic YB-1 expression at the IF (**C**). Median DSS in patients with high/low cytoplasmic YB-1 expression in TC (**D**). The colour reproduction of this figure is available at the *British Journal of Cancer* online.](bjc2011491f3){#fig3}

![Kaplan--Meier plot illustrating DSS within the subgroup of patients with grade 2 HNSSC tumours sub divided according their YB-1 expression at the IF. Low nuclear and cytoplamatic YB-1 expression: continuous upper blue line; high nuclear and cytoplasmic YB-1 expression: dotted lower red line (**A**). YB-1 protein expression determined by immunohistochemistry identifies low- and high-risk grade 2 HNSCC patients. The 5-year DSS rates of histological grade G1, G2, and G3 patients in comparison to sub divided grade 2 HNSCC patients with low YB-1 expression in the nucleus and cytoplasm, and high nuclear and cytoplasmic YB-1 expression (co-expression pattern) (**B**).](bjc2011491f4){#fig4}

###### Baseline and treatment characteristics of HNSCC patients and associated histomorphological data

                                        **Number of cases (%)**
  ------------------------------------- -------------------------
  Patients                              365 (100)
                                         
  *Age (years)*                         
   ⩽50                                  13 (3.6)
   \>50                                 352 (96.4)
                                         
  *Gender*                              
   Male                                 291 (79.7)
   Female                               74 (20.3)
                                         
  *Tumour size*                         
   pT1                                  166 (45.5)
   pT2                                  115 (31.5)
   pT3                                  39 (10.7)
   pT4                                  45 (12.3)
                                         
  *Nodal status*                        
   pN0                                  148 (40.5)
   pN1                                  64 (17.5)
   pN2                                  100 (24.4)
   pN3                                  2 (0.6)
   pNX                                  51 (14.0)
                                         
  *Distant metastasis (at any time)*    
   Absent                               303 (83)
   Present                              64 (17)
                                         
  *Degree of differentiation (grade)*   
   G1                                   27 (7.4)
   G2                                   202 (55.3)
   G3                                   136 (37.3)
                                         
  *Recurrence at 5 years*               
   0                                    303 (79.7)
   +                                    62 (20.3)
                                         
  5-year DSS                            192 (53.0)

Abbreviations: DSS=disease-specific survival; HNSCC=head and neck squamous cell carcinoma.

The term distant metastasis refers to the presentation with any metastasis from the primary or recurrent HNSCC during the whole study duration of 156 months.

###### Association of high/low cytoplasmic (A) and nuclear (B) YB-1 expression at the IF or TC on 5-year DSS (%) in relation to histological grading

        **IF**   **TC**                        
  ----- -------- -------- --------- ----- ---- ---------
  *A*                                          
   G1   100      81       *NS*      100   77   *NS*
   G2   42       57       *0.031*   38    58   *0.012*
   G3   39       62       *NS*      45    53   *NS*
                                                
  *B*                                          
   G1   71       89       *NS*      71    85   *NS*
   G2   39       67       *0.001*   44    60   *0.019*
   G3   43       61       *NS*      46    56   *NS*

Abbreviations: DSS=disease-specific survival; IF=invasion front; TC=tumour center; YB-1=Y-box-binding protein-1. *P*-values below 0.05 are in italics.

###### Multivariate Cox proportional hazards regression analysis to define the statistically independent impact of nuclear YB-1 expression on DSS of HNSCC patients

                                                               ***β***   ***P***   **Exp (*β*)**   **Lower CI**   **Higher CI**
  ------------------------------------------------------------ --------- --------- --------------- -------------- ---------------
  *A*                                                                                                             
   Age                                                         0.016     *NS*      1.016           0.998          1.035
   Grading                                                     −0.016    *NS*      0.984           0.694          1.396
   Tumour size (T1--T4)                                        −0.032    *NS*      0.968           0.808          1.161
   Lymph node involvement (N0--N2)                             0.374     *0.001*   1.454           1.162          1.819
   Nuclear YB-1 overexpression IF (low/high)                   0.776     *0.002*   2.172           1.343          3.512
                                                                                                                   
  *B*                                                                                                             
   Age                                                         0.030     *0.010*   1.030           1.007          1.053
   Grading                                                     0.123     *NS*      1.131           0.662          1.933
   Tumour size (T1--T4)                                        −0.150    *NS*      0.861           0.643          1.152
   Lymph node involvement (N0--N2)                             0.385     *0.001*   1.469           1.171          1.844
   Nuclear and cytoplasmic YB-1 overexpression IF (low/high)   1.011     *0.014*   2.747           1.226          6.155

Abbreviations: CI=confidence interval; YB-1=Y-box-binding protein-1.

Nuclear YB-1 expression at the IF (A) and the co-expression pattern (nuclear and cytoplasmic YB-1 expression) of YB-1 at the IF (B) emerged as a statistically independent cancer biomarker to predict DSS of HNSCC patients. *P*-values below 0.05 are in italics.

###### Influence of T and N on 5-year disease-specific survival rate in % (5-year %) depending on solely nuclear or combined nuclear and cytoplasmic YB-1 expression at the IF

          **IF: nuclear YB-1 expression**  **IF: nuclear+cytoplasic YB-1 expression**                                
  ------ --------------------------------- -------------------------------------------- ---- ------------ ----- ---- ------------
   *T*                                                                                                               
    T1                  Low                71                                           52   *0.014*      74    20   *\< 0.001*
                       High                50                                           41                30    23    
    T2                  Low                70                                           34   *\< 0.001*   80    15   *0.011*
                       High                38                                           56                44    34    
    T3                  Low                56                                           5    *NS*         ---   2    *NS*
                       High                44                                           20                45    17    
    T4                  Low                85                                           7    *NS*         ---        ---
                       High                48                                           28                55    11    
                                                                                                                      
   *N*                                                                                                               
    N0                  Low                86                                           52   *0.001*      83    24   *NS*
                       High                58                                           44                68    23    
    N1                  Low                75                                           17   *NS*         100   2    *NS*
                       High                56                                           29                58    17    
    N2                  Low                51                                           19   *NS*         58    10   *NS*
                       High                25                                           54                24    39    

Abbreviations: IF=invasion front; *n*=number of patients at the beginning of 5-year follow-up period; N=nodal status; NS=no statistically significant difference; T=tumour size. *P*-values below 0.05 are in italics.

[^1]: These authors contributed equally to this work.
